New Delhi, May 1 -- Nutrition-tracking platform Healthify is banking on weight-loss drugs to boost growth, anticipating demand for these medicines to boom in India.

The company is increasing its offerings to incorporate GLP-1 drugs such as Ozempic and Mounjaro - used to treat type 2 diabetes and, in some cases, obesity - and expects revenue from its GLP-1 companion programmes to exceed Healthify's main revenue in three to four years, Tushar Vashisht, co-founder and CEO, toldMint in an interview.

The healthtech firm, which started out as a calorie and nutrition-tracking app, expects demand for weight-loss drugs to surge in India.

"Adoption of the drugs will happen very rapidly as prices come down. What we are hopeful to do is to pioneer...